Clinical effect of the SCMC APL-2010 regimen in treatment of acute promyelocytic leukemia in children: an analysis of 44 cases.
- Author:
Zhuo WANG
1
;
Shu-Hong SHEN
;
Yan-Jing TANG
;
Hui-Liang XUE
;
Wen-Ting HU
;
Ci PAN
;
Jing-Yan TANG
;
Long-Jun GU
;
Jing CHEN
Author Information
1. Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. chen-jing@scmc.com.cn.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Child;
Disease-Free Survival;
Humans;
Leukemia, Promyelocytic, Acute;
Male;
Remission Induction;
Retrospective Studies;
Treatment Outcome;
Tretinoin
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(11):1073-1078
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical effect of the SCMC APL-2010 regimen in the treatment of acute promyelocytic leukemia (APL) in children.
METHODS:A retrospective analysis was performed for the clinical data of 44 children with APL who received treatment with the SCMC APL-2010 regimen between April 2010 and July 2016. The Kaplan-Meier survival analysis was used to evaluate event-free survival (EFS) rate and overall survival (OS) rate.
RESULTS:Of the 44 children with APL, 42 (95%) achieved a complete remission (CR) after one course of treatment and 1 achieved CR after two courses of treatment, with an overall CR rate of 98%. The 9-year EFS and OS rates were 96%±3% and 97.7%±2.2% respectively. As for adverse events, 41 (93%) had infection, 29 (66%) had granulocyte reduction, 12 (27%, 1 died) had differentiation syndrome, 16 (36%) had liver dysfunction, 12 (27%) had adverse gastrointestinal reactions, and 7 (16%) had QT prolongation, 1 (2%) had orchitis, and no secondary neoplasm was observed.
CONCLUSIONS:Children with APL receiving the SCMC APL-2010 regimen have a good prognosis and can achieve a long-term survival, while treatment-related infection is commonly seen.
